Results from a 20-year, cohort study add to the evidence that depression increases the risk of developing an autoimmune disease, specifically SLE in women. Lead investigator Andrea Roberts, PhD, says, “There may be direct biological effects of depression that increase the risk of autoimmune disease.”…
Mortality Trends in Lupus Nephritis
According to results of a recent study of all-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014, the all-cause premature mortality rate improved among white, African American and Hispanic patients, with reduced risk of death from CVD and infection. Jorge et al. observed a 32% reduction in mortality. This improved survival may be explained by a combination of improvements in the management of ESRD and of underlying SLE…
Alterations in Macrophage Activation May Signal a Lupus Flare
New data suggest myeloid cells in SLE patients skew B and T cell activation status toward the M1 proinflammatory phenotype, thereby directing SLE flares and remission…
PAD2 & PAD4 Modulate Immune Response in TLR-7-Dependent Lupus
A study in mice suggests that targeting peptidyl arginine deiminases in lupus patients may have a therapeutic role in T cell-mediated diseases, affecting innate and adaptive immunity, as well as modulating dysregulated toll-like receptor 7-dependent immune responses…
Intronic Polymorphism Associated with Risk of Neurological Disorders in SLE
Patients who develop neuropsychiatric symptoms of SLE have a small nucleotide polymorphism (SNP) in an intron in a Ca++ ion channel gene that influences some, but not all, events regulated by Ca++. The SNP appears to influence activation induced apoptosis rates and cytokine production, specifically IL-4, in a disease- and genotype-specific manner…
Silent Cardiac Impairment in SLE
Drug-naive, new-onset SLE patients, even those with inactive disease, are likely to have silent cardiac impairment, according to a new study by Guo et al. Cardiac involvement is the leading cause of death in patients with lupus, and the estimates of cardiac impairment in SLE range from 31–70%. Cardiac impairment can remain unrecognized until after autopsy. These researchers investigated the use of cardiac MRI to explore early warning signs of silent cardiac involvement in SLE and determine treatment timing…
Ustekinumab May Be Effective for Lupus
New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…
Physical & Cognitive Function in SLE Patients
New research used multidomain function assessment to better understand the physical and cognitive functioning of systemic lupus erythematosus (SLE) patients. The pilot study found a high prevalence of impairment in SLE patients, similar to or exceeding the prevalence seen in the general geriatric population. Patients scored lower for lower body strength and low average for cognitive flexibility and attention…
Promote Pregnancy Wellness: Data Can Help Guide Pregnancy Management in Lupus
AMSTERDAM—Clinicians who are counseling women with systemic lupus erythematosus (SLE) have the benefit of an array of new insights into factors linked with increased risk of pregnancy loss, how SLE therapies affect pregnancy and data on outcomes of children born to mothers with SLE, an expert said in a session at EULAR: the Annual European…
Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE
A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 12
- Next Page »